达雷妥尤单抗联合来那度胺/地塞米松治疗未治多发性骨髓瘤:MAIA研究关键亚组分析
MAIA研究事后分析(中位随访64.5个月)显示,在不适合移植的初治多发性骨髓瘤患者中,D-Rd较Rd在多数临床重要亚组中改善无进展生存,包括≥75岁、衰弱、高危细胞遗传学及孤立性gain(1q21)患者;各亚组中D-Rd的总缓解率、MRD阴性率及持续≥12个月MRD阴性率均更高。
要点
- 在中位随访64.5个月的事后分析中,D-Rd较Rd在多数临床重要亚组中改善PFS。
- ≥75岁患者中,D-Rd较Rd的PFS HR为0.59(95%CI 0.44-0.79)。
- ≥75岁患者中,D-Rd与Rd的3/4级及严重TEAE发生率相似,但D-Rd因TEAE停药率更低。
核心结论
- 结果支持在高危患者中使用D-Rd,并支持D-Rd作为不适合移植的初治多发性骨髓瘤的标准治疗。
研究设计与样本
- MAIA研究的事后亚组分析,中位随访64.5个月;不适合移植的初治多发性骨髓瘤患者按1:1随机接受D-Rd或Rd。
主要发现
- 在多数亚组中D-Rd较Rd改善PFS:≥75岁患者HR 0.59(95%CI 0.44-0.79),衰弱患者HR 0.64(95%CI 0.48-0.85)。
- 高危细胞遗传学患者D-Rd较Rd的PFS HR为0.59(95%CI 0.44-0.80),孤立性gain(1q21)患者HR为0.36(95%CI 0.19-0.67)。
- 各亚组中D-Rd较Rd的总缓解率、MRD阴性率(10^-5)及持续≥12个月MRD阴性率均更高。
- ≥75岁患者中,D-Rd与Rd的3/4级及严重治疗中出现的不良事件(TEAE)发生率相似,但D-Rd因TEAE停药率更低。
临床怎么用
- 作者结论认为结果支持在高危患者中使用D-Rd,并支持D-Rd作为不适合移植的初治多发性骨髓瘤的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the MAIA study (median follow-up, 56.2 months), daratumumab plus lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival (PFS) and overall survival versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM). In this post hoc analysis of clinically important subgroups in MAIA (median follow-up, 64.5 months), transplant-ineligible patients with NDMM were randomized 1:1 to D-Rd or Rd. The primary endpoint was PFS; secondary endpoints included overall response rate (ORR) and measurable residual disease (MRD)-negativity rate (10-5). PFS favored D-Rd versus Rd in most subgroups, including patients aged ≥75 years (HR, 0.59; 95% CI, 0.44-0.79), frail patients (HR, 0.64; 95% CI, 0.48-0.85), patients with high-risk cytogenetics (HR, 0.59; 95% CI, 0.44-0.80), and patients with isolated gain(1q21) (HR, 0.36; 95% CI, 0.19-0.67). ORRs, MRD-negativity rates, and sustained (≥12 months) MRD-negativity rates were higher with D-Rd versus Rd across subgroups. In patients aged ≥75 years, rates of grade 3/4 and serious treatment-emergent adverse events (TEAEs) were similar for D-Rd and Rd, but discontinuation due to TEAEs was lower for D-Rd. Results support use of D-Rd for high-risk patients, supporting D-Rd as a standard of care for transplant-ineligible NDMM. This trial was registered at www.clinicaltrials.gov as NCT02252172.
引用
- Moreau P, Facon T, Usmani SZ, et al. Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study. Leukemia. 2025. PMID: 39815052. doi:10.1038/s41375-024-02506-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。